![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_BMS_Evotec_072382e6ec.png)
Evotec SE cashes in €20m milestone
The partnership initiated in 2016 uses Evotec’s iPSC platform to create predictive patient-derived cell-based disease models that mimic the pathology...
![](/fileadmin/_processed_/csm_Evotec_HQ_516a5db450.jpg)
Consortium led by Evotec enters obesity drug space
The newly formed strategic partnership between Evotec SE, Inserm, Lille University Hospital and Inserm Transfert aims to identify novel multimodal...
![](/fileadmin/_processed_/csm_Peter_Sondermann__c__Tacalyx_d5b3b6d2e0.jpg)
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...
![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
![](/fileadmin/_processed_/csm_Amphistar_c6faa8b918.jpg)
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
![](/fileadmin/_processed_/csm_Roche3_cd0afd0272.png)
Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...